Three stocks that offer yields of more than 3% and which are trading near their 52-week lows today are Merck ( MRK -0.81%), ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Merck is going all-in on domestic drug manufacturing with a $1 billion Delaware facility aimed at dodging Trump-era tariff ...

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 construction jobs expected on the job site. The laboratory component of the new site ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Officials with Merck Biopharmaceutical Company broke ground on a new, 470,000 square foot biologics center at the Chestnut ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...